Evidence map›Paper›PMID 34193311›Full record

ArticleImplementation science communications2021

Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.

Fred C Semitala, Allan Musinguzi, Jackie Ssemata, Fred Welishe, Juliet Nabunje, Jillian L Kadota, Christopher A Berger, Achilles Katamba, Noah Kiwanuka, Moses R Kamya and 3 more

Open access · goldAbstract read
In one paragraph

Article in Implementation science communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Fred C Semitala *Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. semitala@gmail.com.ORCID http://orcid.org/0000-0002-0624-7640
Allan Musinguzi *Infectious Diseases Research Collaboration, Kampala, Uganda.
Jackie SsemataInfectious Diseases Research Collaboration, Kampala, Uganda.
Fred WelisheInfectious Diseases Research Collaboration, Kampala, Uganda.
Juliet NabunjeInfectious Diseases Research Collaboration, Kampala, Uganda.
Jillian L KadotaDivision of Pulmonary and Critical Care Medicine and Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA.
Christopher A BergerDivision of Pulmonary and Critical Care Medicine and Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA.
Achilles KatambaDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Noah KiwanukaSchool of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Moses R KamyaDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
David DowdyUganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Adithya CattamanchiDivision of Pulmonary and Critical Care Medicine and Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA.
Anne R KatahoireDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Infectious Diseases Research Collaboration · UGMakerere University · UGUniversity of California, San Francisco · USJohns Hopkins University · USSan Francisco General Hospital · US

Funding

Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialR01HL144406 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adithya Cattamanchi, David Wesley Dowdy · 2018 to 2026
$4.4M
NHLBI NIH HHS NIH/NHLBI R01HL144406NHLBI NIH HHS R01 HL144406
6 · The paper itself

Abstract

backgroundA 12-dose, once-weekly regimen of isoniazid and rifapentine (3HP) is effective in preventing tuberculosis (TB) among people living with HIV (PLHIV). We sought to identify potential barriers to and facilitators of acceptance and completion of 3HP treatment from the perspective of people living with HIV (PLHIV) and health workers in a routine HIV care setting in Kampala, Uganda.

methodsWe conducted semi-structured interviews with 25 PLHIV and 10 health workers at an HIV/AIDS clinic in Kampala, Uganda. For both groups, we explored their understanding and interpretations of TB and TB preventive therapy (TPT), and perceptions about social and contextual factors that might influence the willingness of PLHIV to initiate and complete 3HP. We analyzed the data using an inductive thematic approach and aligned the emergent themes to the Behavior Change Wheel framework to identify sources of behavior and targeted behavior change interventions.

resultsFacilitators of acceptance and completion of 3HP treatment among PLHIV were fear of contracting TB, awareness of being at risk of getting TB, willingness to take TPT, trust in health workers, and the perceived benefits of directly observed therapy (DOT) and self-administered therapy (SAT) 3HP delivery strategies. Barriers included inadequate understanding of TPT, fear of potential side effects, concerns about the effectiveness of 3HP, and the perceived challenges of DOT or SAT. Among health workers, perceived facilitators included knowledge that TB is a common cause of mortality for PLHIV, fear of getting TB, and trust in the health workers by PLHIV, the advantages of once-weekly 3HP dosing, and the benefits of DOT and SAT 3HP delivery strategies. Health worker-reported barriers for PLHIV included inadequate understanding of TB and benefits of TPT, TB-associated stigma, potential side effects pill burden, and challenges of DOT and SAT 3HP delivery strategies. Lack of experience in the use of digital technology to monitor patient care was identified as a health worker-specific barrier. Identified intervention functions to address the facilitators or barriers included education, persuasion, environmental restructuring, enablement, and training.

conclusionsUsing a formative qualitative and comprehensive theoretical approach, we identified key barriers, facilitators, and appropriate interventions, including patient education, enhancing trust, and patient-centered treatment support that could be used to optimize the delivery of 3HP to PLHIV in our setting. These interventions are likely generalizable to other clinical interventions in similar populations in sub-Saharan Africa and other TB high-burden settings.

Indexed as

Health workersImplementationPeople living with HIVPerceived barriersPerceived facilitatorsPreventive therapyQualitative methodsTuberculosis

Identifiers

PMID34193311
PMCPMC8247167
OpenAlexW3108558285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.